| Profile In American Innovation: Science And Business Leaders Convene For The Dry Eye Summit In Fort Lauderdale |
On Friday, April 30, the world's thought leaders in dry eye drug development will gather in Ft. Lauderdale, Florida for the inaugural Dry Eye Summit. |
| DIAGNOS Signs an Agreement with Ora: Consulting for the U.S. Food and Drug Administration (FDA) Registration Process |
DIAGNOS inc., a leader in the use of artificial intelligence and advanced knowledge extraction techniques, and Ora, Inc. ("Ora"), a leader in ophthalmic product development, announced today that they have signed a consulting agreement for the U.S. FDA registration process for CARA (Computer Assisted Retinal Analysis) application with the intention of commercializing services derived from CARA in the United States in the coming months. |
| SDC - ARVO Program |
2010 03 31 Organizers and Speakers Dale Kennedy, PhD, Statistics & Data Corp. Kathryn S. Kennedy, MSE, Statistics & Data Corp. This course is designed for the non statistician clinical research professional who wants to develop a better understanding |
| Eyegate Pharma Annouces that EGP-437 Improved Signs and Symptoms of Dry Eye Syndrome in a Phase II Study |
2009 06 03 Waltham, MA Based on the top level analysis of a Phase II study, EyeGate Pharma announces that EGP 437, a corticosteroid solution administered by a non invasive ocular drug delivery system, improved signs and symptoms in |
| Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis |
PARIS,France/PRNewswire/ -- Fovea Pharmaceuticals announced today positive results from its clinical proof-of-concept trial to assess the therapeutic effect of Prednisporin(TM) (FOV1101) in patients with persistent allergic conjunctivitis. |
| Novagali Pharma completed a new Phase II with Cyclokat® in dry eye |
Novagali Pharma, a French pharmaceutical ophthalmic company, today announces successful completion of a new Phase II clinical study with Cyclokat ® , its formulation of Cyclosporine. The results demonstrate statistically significant improvement with signs and symptoms |
| EYEGATE PHARMA COMPLETES PHASE II CLINICAL TRIAL - Results Expected in 2nd Quarter 2009 |
EyeGate Pharma, the leader in non-invasive ocular drug delivery, today announces that they have fully enrolled and completed all follow-up visits for all patients participating in their Phase II safety and efficacy study of EGP-437 (a combination drug/device) for treating Dry Eye Syndrome. The results of this study are expected in the second quarter of 2009. |